Europe Frontotemporal Dementia Market By Drug Class Type (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, Others), By Disease Type (Frontotemporal Dementia, Primary Progressive Aphasia Others), By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Others), By Country, Competition, Forecast & Opportunities, 2028

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Europe frontotemporal dementia market is expected to witness significant growth during the forecast period, 2024-2028. Growing prevalence of dementia along with growing aging population in the region is anticipated to facilitate the growth of the market. The gradual increase in the number of new cases of dementia registered directly every year are strengthening the growth of the frontotemporal dementia market. Moreover, the rising fundings provided by government as well as by the several non-profit organizations for the target disease care, support, and R&D activities to develop new drug are the major factor propelling the growth of the market. Furthermore, the advent of novel Frontotemporal dementia therapies as well as new diagnosing biomarkers are projected to augment the growth of the market. Rising number of clinical trials in the region are propelling the growth of the market.

Frontotemporal dementia refers to a group of uncommon brain disorders that primarily affect the frontal and temporal lobes of the brain. These areas of the brain are generally associated with personality, behavior and language. It often begins between the age of 40 and 65.

Growing Prevalence of Dementia

Growing incidence of dementia among European people are likely to impel the growth of the market.  In 2019, the occurrence of dementia in Europe was roughly 188 per 100,000 population. The growing geriatric population is more susceptible to dementia than younger generation, due to their rising age, which, in turn, is projected to propel the growth of the market. In 2019, about 45 percent of women and 30 percent of men with the age 90 years and above were living with dementia in Europe. Generally, the share of women living with dementia in Europe was much higher when compared to men.

Increasing Number of Clinical Trials

There are large number of clinical studies which are going on for the frontotemporal dementia in the region, which is projected to bolster the growth of the market. There is total 25 clinical studies which are completed in Europe. For instance, in 2019, a clinical trial for the device named transcranial direct current stimulation (tDCS) was completed under the study name of “Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia”.

Recent Developments

  • In 2022, AviadoBio, a pioneering, pre-clinical stage, gene therapy company emphasized on developing and delivering transformative medicines for patients with neurodegenerative disorders, announced that both the U.S. Food and Drug Administration (FDA) and the European Commission (EC) have granted orphan designation to AVB-101, a one-time gene therapy for the treatment of frontotemporal dementia (FTD).
  • In 2021, Centogene N.V., a commercial-stage company emphasized on producing data-driven insights to diagnose, understand, and treat rare diseases, announced that they have enrolled first patient in the international EFRONT Study, an observational study to know the prevalence of genetic mutations in patients with frontotemporal dementia (FTD).


Download Free Sample Report

Market Segmentation

Europe frontotemporal dementia market is segmented into drug class type, disease type, end user and region. Based on drug class type, the market is divided into cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and others. Based on disease type, the market is bifurcated into frontotemporal dementia, primary progressive aphasia, and others. Based on end user, the market is divided into hospitals & clinics, ambulatory surgery centers, and others. In terms of countries, the market is categorized into France, Germany, United Kingdom, Italy, Spain, Belgium, Netherlands, Switzerland, Poland, and Sweden.

Market Players

GlaxoSmithKline PLC, Eli Lilly Italia S.p.A., Pfizer Deutschland GmbH., F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca GmbH, Sanofi S.A, Allergen plc, Johnson & Johnson and Viatris Inc are some of the leading companies operating in the Europe Frontotemporal Dementia market.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million and CAGR for 2018-2022 and 2023-2028

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

·         Drug Class Type

·         Disease Type

·         End User

·         Country

Country scope

France, Germany, United Kingdom, Italy, Spain, Belgium, Netherlands, Switzerland, Poland, and Sweden.

Key companies profiled

GlaxoSmithKline PLC, Eli Lilly Italia - S.P.A., Pfizer Deutschland GmbH., F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca GmbH, Sanofi S.A, Allergen plc, Johnson & Johnson and Viatris Inc.

Customization scope

10% free report customization with purchase. Addition or alteration to country, & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Report Scope:

In this report, Europe frontotemporal dementia market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Europe Frontotemporal Dementia Market, By Drug Class Type:
    • Cognitive Enhancers
    • Antipsychotics
    • Antidepressants
    • CNS Stimulants
    • Others
  • Europe Frontotemporal Dementia Market, By Disease Type:
    • Frontotemporal Dementia
    • Primary Progressive Aphasia
    • Others
  • Europe Frontotemporal Dementia Market, By End User:
    • Hospitals & Clinics
    • Ambulatory Surgery Centers
    • Others
  • Europe Frontotemporal Dementia Market, By Country:
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
    • Belgium
    • Netherlands
    • Switzerland
    • Poland
    • Sweden

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Europe frontotemporal dementia market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.
It is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Europe Frontotemporal Dementia Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Drug Class Type (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, Others)

5.2.2.     By Disease Type (Frontotemporal Dementia, Primary Progressive Aphasia, Others)

5.2.3.     By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Others)

5.2.4.     By Company (2022)

5.2.5.     By Country

5.3.  Market Map

5.3.1.     By Drug Class Type

5.3.2.     By Disease Type

5.3.3.     By End User

5.3.4.     By Country

5.4.  Europe: Country Analysis

5.4.1.     Germany Frontotemporal Dementia Market Outlook

5.4.1.1.         Market Size & Forecast

5.4.1.1.1.             By Value

5.4.1.2.         Market Share & Forecast

5.4.1.2.1.             By Drug Class Type

5.4.1.2.2.             By Disease Type

5.4.1.2.3.             By End User

5.4.2.     France Frontotemporal Dementia Market Outlook

5.4.2.1.         Market Size & Forecast

5.4.2.1.1.             By Value

5.4.2.2.         Market Share & Forecast

5.4.2.2.1.             By Drug Class Type

5.4.2.2.2.             By Disease Type

5.4.2.2.3.             By End User

5.4.3.     United Kingdom Frontotemporal Dementia Market Outlook

5.4.3.1.         Market Size & Forecast

5.4.3.1.1.             By Value

5.4.3.2.         Market Share & Forecast

5.4.3.2.1.             By Drug Class Type

5.4.3.2.2.             By Disease Type

5.4.3.2.3.             By End User

5.4.4.     Italy Frontotemporal Dementia Market Outlook

5.4.4.1.         Market Size & Forecast

5.4.4.1.1.             By Value

5.4.4.2.         Market Share & Forecast

5.4.4.2.1.             By Drug Class Type

5.4.4.2.2.             By Disease Type

5.4.4.2.3.             By End User

5.4.5.     Spain Frontotemporal Dementia Market Outlook

5.4.5.1.         Market Size & Forecast

5.4.5.1.1.             By Value

5.4.5.2.         Market Share & Forecast

5.4.5.2.1.             By Drug Class Type

5.4.5.2.2.             By Disease Type

5.4.5.2.3.             By End User

5.4.6.     Belgium Frontotemporal Dementia Market Outlook

5.4.6.1.         Market Size & Forecast

5.4.6.1.1.             By Value

5.4.6.2.         Market Share & Forecast

5.4.6.2.1.             By Drug Class Type

5.4.6.2.2.             By Disease Type

5.4.6.2.3.             By End User

5.4.7.     Netherlands Frontotemporal Dementia Market Outlook

5.4.7.1.         Market Size & Forecast

5.4.7.1.1.             By Value

5.4.7.2.         Market Share & Forecast

5.4.7.2.1.             By Drug Class Type

5.4.7.2.2.             By Disease Type

5.4.7.2.3.             By End User

5.4.8.     Switzerland Frontotemporal dementia Market Outlook

5.4.8.1.         Market Size & Forecast

5.4.8.1.1.             By Value

5.4.8.2.         Market Share & Forecast

5.4.8.2.1.             By Drug Class Type

5.4.8.2.2.             By Disease Type

5.4.8.2.3.             By End User

5.4.9.     Poland Frontotemporal dementia Market Outlook

5.4.9.1.         Market Size & Forecast

5.4.9.1.1.             By Value

5.4.9.2.         Market Share & Forecast

5.4.9.2.1.             By Drug Class Type

5.4.9.2.2.             By Disease Type

5.4.9.2.3.             By End User

5.4.10.  Sweden Frontotemporal dementia Market Outlook

5.4.10.1.      Market Size & Forecast

5.4.10.1.1.           By Value

5.4.10.2.      Market Share & Forecast

5.4.10.2.1.           By Drug Class Type

5.4.10.2.2.           By Disease Type

5.4.10.2.3.           By End User

6.    Market Dynamics

6.1.  Drivers

6.2.  Challenges

7.    Market Trends & Developments

8.    Competitive Landscape

8.1.  Business Overview

8.2.  Product Offerings

8.3.  Recent Developments

8.4.  Financials (As Reported)

8.5.  Key Personnel

8.6.  SWOT Analysis

8.6.1.     GlaxoSmithKline PLC

8.6.2.     Eli Lilly Italia - S.P.A.

8.6.3.     Pfizer Deutschland GmbH.

8.6.4.     F. Hoffmann-La Roche Ltd.

8.6.5.     Novartis AG

8.6.6.     AstraZeneca GmbH

8.6.7.     Sanofi S.A

8.6.8.     Allergen plc

8.6.9.     Johnson & Johnson

8.6.10.  Viatris Inc.

9.    Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

Growing clinical trials, rising incidences of demntia, and increasing R&D activities are driving the demand for the Europe frontotemporal dementia market.

down-arrow

GlaxoSmithKline PLC, Eli Lilly Italia S.p.A., Pfizer Deutschland GmbH., F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca GmbH, Sanofi S.A, Allergen plc, Johnson & Johnson and Viatris Inc are the key players operating in the Europe frontotemporal dementia market.

down-arrow

On the basis of type, the Europe frontotemporal dementia market the market can be categorized into cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and others. The antidepressants segment is expected to dominate the growth of the market. This is attributed to the wide use of antidepressants to treat major depressive disorders and other illnesses such as anxiety disorders, obsessive-compulsive disorder (OCD), chronic pain, and neuropathic pain.

down-arrow

The lack of awareness among people about the disorder as well as the cost issues in the region are likely to slow down the growth of Europe frontotemporal dementia market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Europe Frontotemporal Dementia Market to Witness Significant Growth until 2025

Jun, 2020

Increasing funding by government for R&D activities and rising life expectancy rate to drive Europe frontotemporal dementia market

Why Choose Us